Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Search form

GW Pharmaceuticals is Honored to be Named As One of TIME’s 50 Genius Companies For Its Work in Advancing Cannabinoid Science

Recent News

Oct 05, 2018
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs
London, UK, Carlsbad, CA, 5 October 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of
Read more...
Oct 02, 2018
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million
London, UK, Carlsbad, CA, 2 October 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company.
Read more...
Oct 01, 2018
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
London, UK, Carlsbad, CA, 1 October 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform and whose U.S.
Read more...
View More

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Approved
Epidiolex
Lennox-Gastaut Syndrome
Approved
Epidiolex
Tuberous Sclerosis
Phase 3
Epidiolex
Rett Syndrome
Completed Phase 2

Sativex (U.S.)

Sativex
Ms Spasticity
Completed Phase 3
Sativex
Neuropathic Pain / Other Neurological Symptoms
Completed Phase 2

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Phase 2

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioblastoma
Phase 2
GWP42003
Schizophrenia
Phase 2
Learn More